VERTEX PHARMACEUTICALS INC (VRTX) Stock Price, Quote, News and Overview
NASDAQ:VRTX - Nasdaq - US92532F1003 - Common Stock - Currency: USD
VRTX Quote, Performance and Key Statistics
447.18
+6.52 (+1.48%)
The current stock price of VRTX is 447.18 USD. In the past month the price decreased by -8.83%. In the past year, price decreased by -2.14%.
VRTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18 | 327.00B | ||
| AMGN | AMGEN INC | 13.25 | 147.86B | ||
| GILD | GILEAD SCIENCES INC | 14.1 | 135.84B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.87 | 66.38B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.94B | ||
| ARGX | ARGENX SE - ADR | 98.52 | 35.31B | ||
| ONC | BEIGENE LTD-ADR | 5.89 | 25.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.45B | ||
| NTRA | NATERA INC | N/A | 21.01B | ||
| BIIB | BIOGEN INC | 8.25 | 19.13B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.11B | ||
| UTHR | UNITED THERAPEUTICS CORP | 12.35 | 13.96B |
Related stock screener links
About VRTX
Company Profile
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,100 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Company Info
VERTEX PHARMACEUTICALS INC
50 Northern Avenue
Boston MASSACHUSETTS 02210 US
CEO: Reshma Kewalramani
Employees: 6100
Phone: 16173416393
VERTEX PHARMACEUTICALS INC / VRTX FAQ
What is the stock price of VERTEX PHARMACEUTICALS INC today?
The current stock price of VRTX is 447.18 USD. The price increased by 1.48% in the last trading session.
What is the ticker symbol for VERTEX PHARMACEUTICALS INC stock?
The exchange symbol of VERTEX PHARMACEUTICALS INC is VRTX and it is listed on the Nasdaq exchange.
On which exchange is VRTX stock listed?
VRTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for VERTEX PHARMACEUTICALS INC stock?
40 analysts have analysed VRTX and the average price target is 516.28 USD. This implies a price increase of 15.45% is expected in the next year compared to the current price of 447.18. Check the VERTEX PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VERTEX PHARMACEUTICALS INC worth?
VERTEX PHARMACEUTICALS INC (VRTX) has a market capitalization of 114.96B USD. This makes VRTX a Large Cap stock.
How many employees does VERTEX PHARMACEUTICALS INC have?
VERTEX PHARMACEUTICALS INC (VRTX) currently has 6100 employees.
What are the support and resistance levels for VERTEX PHARMACEUTICALS INC (VRTX) stock?
VERTEX PHARMACEUTICALS INC (VRTX) has a support level at 422.16 and a resistance level at 464.06. Check the full technical report for a detailed analysis of VRTX support and resistance levels.
Is VERTEX PHARMACEUTICALS INC (VRTX) expected to grow?
The Revenue of VERTEX PHARMACEUTICALS INC (VRTX) is expected to grow by 9.5% in the next year. Check the estimates tab for more information on the VRTX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VERTEX PHARMACEUTICALS INC (VRTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of VRTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of VRTX, evaluating the profitability, health, valuation and growth aspects
- VERTEX PHARMACEUTICALS INC (VRTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VERTEX PHARMACEUTICALS INC (VRTX) Sales and EPS estimates to see what analysts future expectations are.
- VERTEX PHARMACEUTICALS INC (VRTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VERTEX PHARMACEUTICALS INC (VRTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- VERTEX PHARMACEUTICALS INC (VRTX) Stock Chart to make your own analysis
- VERTEX PHARMACEUTICALS INC (VRTX) Latest news and press-releases to stay up to date.
Does VERTEX PHARMACEUTICALS INC (VRTX) stock pay dividends?
VRTX does not pay a dividend.
When does VERTEX PHARMACEUTICALS INC (VRTX) report earnings?
VERTEX PHARMACEUTICALS INC (VRTX) will report earnings on 2025-07-30, after the market close.
What is the Price/Earnings (PE) ratio of VERTEX PHARMACEUTICALS INC (VRTX)?
VERTEX PHARMACEUTICALS INC (VRTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.41).
What is the Short Interest ratio of VERTEX PHARMACEUTICALS INC (VRTX) stock?
The outstanding short interest for VERTEX PHARMACEUTICALS INC (VRTX) is 1.47% of its float. Check the ownership tab for more information on the VRTX short interest.
VRTX Technical Analysis
VRTX Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to VRTX. VRTX has an average financial health and profitability rating.
VRTX Financial Highlights
Over the last trailing twelve months VRTX reported a non-GAAP Earnings per Share(EPS) of -0.41. The EPS decreased by -102.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.32% | ||
| ROE | -5.99% | ||
| Debt/Equity | 0.01 |
VRTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to VRTX. The Buy consensus is the average rating of analysts ratings from 40 analysts.
For the next year, analysts expect an EPS growth of 6198.7% and a revenue growth 9.5% for VRTX